Lung Cancer

1

What is the optimal radiotherapy schedule for limited stage small cell lung cancer?

Slotman, Ben

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 267 KB

english, 2017

2

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

Salgia, Ravi, Stille, John R., Weaver, R. Waide, McCleod, Michael, Hamid, Oday, Polzer, John, Roberson, Stephanie, Flynt, Amy, Spigel, David R.

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 1.05 MB

english, 2017

3

Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer

Soo, Ross A., Kim, Hye Ryun, Asuncion, Bernadette Reyna, Fazreen, Zul, Omar, Mohamed Feroz Mohd, Herrera, Maria Cynthia, Yun Lim, Joey Sze, Sia, Grace, Soong, Richie, Cho, Byoung-Chul

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 465 KB

english, 2017

4

Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?

Mansfield, Aaron Scott

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 456 KB

english, 2017

5

Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients

Gachechiladze, Mariam, Škarda, Josef, Kolek, Vítězslav, Grygárková, Ivona, Langová, Kateřina, Bouchal, Jan, Kolář, Zdeněk, Baty, Florent, Stahel, Rolf, Weder, Walter, Soltermann, Alex, Joerger, Markus

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 1.65 MB

english, 2017

6

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition

Le, Tri, Sailors, Joseph, Oliver, Dwight H., Mayer, Melissa, Hoskin, Sharon, Gerber, David E.

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 1.48 MB

english, 2017

7

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer

Yonesaka, Kimio, Hirotani, Kenji, von Pawel, Joachim, Dediu, Mircea, Chen, Shuquan, Copigneaux, Catherine, Nakagawa, Kazuhiko

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 720 KB

english, 2017

8

Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening

Veronesi, Giulia, Colombo, Paolo, Novellis, Pierluigi, Crepaldi, Alessandro, Lutman, Romano Fabio, Dieci, Elisa, Profili, Manuel, Siracusano, Licia, Alloisio, Marco

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 291 KB

english, 2017

9

Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer

Katakami, Nobuyuki, Hida, Toyoaki, Nokihara, Hiroshi, Imamura, Fumio, Sakai, Hiroshi, Atagi, Shinji, Nishio, Makoto, Kashii, Tatsuhiko, Satouchi, Miyako, Helwig, Christoph, Watanabe, Morihiro, Tamura,

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 762 KB

english, 2017

10

Editorial Board

Journal:

Lung Cancer

Year:

2017

Language:

english

File:

PDF, 72 KB

english, 2017

11

Volume 105

What is the optimal radiotherapy schedule for limited stage small cell lung cancer?

A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer

Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer

Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?

Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer

Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening

Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer

Editorial Board

Contents